Trajectories of Fasting Blood Glucose in Autologous Hematopoietic Cell Transplantation

Cancer Nursing
Marilyn J HammerChristine Miaskowski

Abstract

Patients who receive autologous hematopoietic cell transplantation (HCT) for the treatment of hematologic malignancies are at risk of serious adverse outcomes including infections and death. Hyperglycemia following the HCT is associated with increased risk of these adverse outcomes. However, limited information is available on demographic and clinical characteristics that contribute to changes in blood glucose levels following HCT. The objective of this study was to determine the trajectories of fasting blood glucose (FBG) levels as well as the demographic and clinical characteristics that predicted interindividual differences in these FBG trajectories. A sample of adult patients with hematologic malignancies who were scheduled to receive autologous HCT (n = 53) was enrolled in the study. Patients with preexisting diabetes were excluded. Demographic and clinical characteristics were abstracted from electronic medical records. Morning fasting laboratory tests (ie, FBG and absolute neutrophil counts) were obtained. Data were analyzed using hierarchical linear modeling from the day of HCT (day 0) through 14 days post-HCT. Among 8 characteristics evaluated, pre-HCT FBG was associated with variability in both the initial levels and ...Continue Reading

References

Feb 27, 2004·Journal of Intensive Care Medicine·W Garrett Nichols
Dec 4, 2004·European Journal of Epidemiology·Jodi Dunmeyer StookeyHarvey Jay Cohen
Jul 12, 2005·Pharmacotherapy·Simona O ButlerCesar Alaniz
Aug 2, 2007·Nature Reviews. Molecular Cell Biology·Judith Campisi, Fabrizio d'Adda di Fagagna
Jul 25, 2008·Nature·Alberto MantovaniFrances Balkwill
Jan 13, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Shigeo FujiUNKNOWN Japan Marrow Donor Program
Feb 11, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Marilyn J HammerIrl B Hirsch
May 19, 2009·Diabetes & Metabolism·U-M VischerUNKNOWN Alfediam/SFGG French-speaking group for study of diabetes in the elderly
Mar 31, 2010·Leukemia & Lymphoma·Charulata RamaprasadDavid L Pitrak
May 7, 2010·Trends in Molecular Medicine·Adam FreundJudith Campisi
Jul 14, 2010·American Journal of Clinical Oncology·Antonella BrunelloMartine Extermann
May 1, 2012·Oncology Nursing Forum·Marilyn J Hammer, Joachim G Voss
Oct 9, 2014·Immunological Investigations·Youssef Mohamed Mosaad
Dec 20, 2014·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Laura B DunnChristine Miaskowski
Feb 28, 2015·Current Diabetes Reports·Brian BoernerJennifer Larsen
Dec 22, 2015·The Lancet. Haematology·Alois GratwohlUNKNOWN Worldwide Network for Blood and Marrow Transplantation (WBMT)
Jan 23, 2016·Biological Research for Nursing·Marilyn J HammerCharles M Cleland
Dec 17, 2016·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

© 2022 Meta ULC. All rights reserved